Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;7(7):R246-R253.
doi: 10.1530/EC-18-0186. Epub 2018 Jul 2.

Bone metabolism in Langerhans cell histiocytosis

Affiliations
Review

Bone metabolism in Langerhans cell histiocytosis

Athanasios D Anastasilakis et al. Endocr Connect. 2018 Jul.

Abstract

Langerhans cell histiocytosis (LCH) is a rare disease of not well-defined etiology that involves immune cell activation and frequently affects the skeleton. Bone involvement in LCH usually presents in the form of osteolytic lesions along with low bone mineral density. Various molecules involved in bone metabolism are implicated in the pathogenesis of LCH or may be affected during the course of the disease, including interleukins (ILs), tumor necrosis factor α, receptor activator of NF-κB (RANK) and its soluble ligand RANKL, osteoprotegerin (OPG), periostin and sclerostin. Among them IL-17A, periostin and RANKL have been proposed as potential serum biomarkers for LCH, particularly as the interaction between RANK, RANKL and OPG not only regulates bone homeostasis through its effects on the osteoclasts but also affects the activation and survival of immune cells. Significant changes in circulating and lesional RANKL levels have been observed in LCH patients irrespective of bone involvement. Standard LCH management includes local or systematic administration of corticosteroids and chemotherapy. Given the implication of RANK, RANKL and OPG in the pathogenesis of the disease and the osteolytic nature of bone lesions, agents aiming at inhibiting the RANKL pathway and/or osteoclastic activation, such as bisphosphonates and denosumab, may have a role in the therapeutic approach of LCH although further clinical investigation is warranted.

Keywords: Langerhans cell histiocytosis (LCH); bisphosphonates; denosumab; osteoporosis; receptor activator of NF-κB ligand (RANKL).

PubMed Disclaimer

Figures

Figure 1
Figure 1
S-100 (panel A), Langerin (panel B) and CD1a (panel C) immunoexpression in Langerhans cell histiocytosis lesions (magnification ×400). Immunostains are indicated in brown color from bone lesions.
Figure 2
Figure 2
Mandibular osteolytic lesion depicted in plain radiograph evaluation (panel A); CT image of an osteolytic iliac bone lesion (panel B); circumscribed osteolytic lesion at the inner section of the right acetabulum with surrounding edema showed in an MRI image (panel C) and the same lesion as depicted in a PET-CT scan image (panel D).

References

    1. Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, Emile JF, Lukina E, De Juli E, Danesino C. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. European Journal of Cancer 2003. 39 2341–2348. (10.1016/S0959-8049(03)00672-5) - DOI - PubMed
    1. Malpas JS. Langerhans cell histiocytosis in adults. Hematology/Oncology Clinics of North America 1998. 12 259–268. (10.1016/S0889-8588(05)70509-8) - DOI - PubMed
    1. Stålemark H, Laurencikas E, Karis J, Gavhed D, Fadeel B, Henter JI. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatric Blood and Cancer 2008. 51 76–81. (10.1002/pbc.21504) - DOI - PubMed
    1. Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J, Haroche J, Kaltsas GA, Makras P, Marzano AV, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet Journal of Rare Diseases 2013. 8 72 (10.1186/1750-1172-8-72) - DOI - PMC - PubMed
    1. PDQ Pediatric Treatment Editorial Board. Langerhans Cell Histiocytosis Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. Bethesda, MD, USA: National Cancer Institute (US), 2017. (available at: https://www.ncbi.nlm.nih.gov/books/NBK65799/) - PubMed

LinkOut - more resources